Skip to main content
Caplight Logo









Attomarker Ltd

Attomarker Ltd

Private
ExeterHealthcare & Life Scienceshttps://attomarker.com/

Last Round

Crowdfunding

Mar 1, 2026

Est. Valuation

$20.95M

Total Funding Raised

$6.85M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Attomarker Ltd is a diagnostics company that develops nanophotonic multiplex blood-testing technology for rapid, personalized medical diagnostics.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Biotech Equipment, Precision Medicine, Sensors, Biotechnology

Business Model

B2B

Customer Profile

Hardware Sales, Services & Consulting, Government Contracts

AI Layer

Application

Keywords

point-of-care diagnosticsmultiplex blood testingnanophotonic sensorsPOC testingpersonalized medicinebiomarker analysisdiagnostic analyzerclinical laboratoryrapid diagnosticsat-home diagnosticsCLIA labmedical devicedigital healthprecision medicinelab-on-a-chip

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Attomarker Ltd Comparables

Compare Attomarker Ltd with similar companies based on industry and business-model similarity.

Attomarker Ltd comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Bialoom Ltd
82%
AgPlus Diagnostics
80%
Truvian
79%

Attomarker Ltd Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
CrowdfundingMar 1, 2026
StrategicMay 5, 2022
GrantDec 18, 2020
Convertible DebtDec 18, 2020
GrantMar 18, 2015

Attomarker Ltd Investors

Notable investors and investment history

Attomarker Ltd investors
InvestorRounds
Milltrust VenturesGrant
Innovate UKGrant
Horizon 2020 SME InstrumentGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 1, 2026

    $42K raised from Crowdcube.

  • May 4, 2025

    Grew 25% QoQ, from 16 to 20 employees.

Attomarker Ltd Filings

Explore SEC and related filing metadata, where available.

Attomarker Ltd filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Attomarker Ltd's valuation, stock price, and market status.

Is Attomarker Ltd a public or private company?

Attomarker Ltd is a private company.

What is the current stock price of Attomarker Ltd?

Attomarker Ltd is a private company with no public stock price. No recent secondary market data is available.

How much is Attomarker Ltd worth (valuation)?

Attomarker Ltd's valuation is estimated at $20.9M based on funding round data.

Can I buy Attomarker Ltd stock?

Attomarker Ltd shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Attomarker Ltd's last funding round?

Attomarker Ltd's most recent funding round was Crowdfunding on March 1, 2026.

Who are the main investors in Attomarker Ltd?

Key investors in Attomarker Ltd include Innovate UK, Horizon 2020 SME Instrument.

Will Attomarker Ltd IPO soon?

No public IPO plans have been announced for Attomarker Ltd.

How can I track Attomarker Ltd secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Attomarker Ltd's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersExeter
Employee Range9
Year Founded2008
Last FundingMar 1, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?